TransCode Therapeutics (NASDAQ: RNAZ) has released updated clinical data from its Phase 1a trial of TTX-MC138, an investigational RNA therapeutic for patients with relapsed or refractory, unresectable locally advanced or metastatic solid tumors. The results, as of September 1, show that 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as their best overall response. Notably, six patients remained progression-free at three months, and three continued progression-free at six, nine, and 12 months, suggesting durable disease control in a heavily pretreated population.
The disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1. A post-hoc Growth Modulation Index (GMI) analysis revealed that six of 15 evaluable patients (40%) achieved a GMI greater than 1.3, indicating a progression-free interval at least 30% longer than with their immediately preceding therapy. This metric is particularly meaningful in oncology, as it compares the current treatment's benefit to the patient's prior therapy, offering a personalized measure of efficacy.
Safety data remain encouraging: a total of 98 doses had been administered as of September 1, with no dose-limiting toxicities and no treatment-emergent adverse events leading to treatment discontinuation, even at the highest evaluated dose of 4.8 mg/kg. Exploratory RNA-sequencing analysis identified treatment-associated immune effects that the company believes support the observed clinical activity, though these biomarker findings require confirmation in larger studies. For a full overview, visit https://ibn.fm/mIBZR.
These results are important because they suggest that TTX-MC138 may offer clinical benefit without the severe toxicity often associated with advanced cancer treatments. The stable disease rates and prolonged progression-free survival in some patients could translate into meaningful improvements in quality of life and overall survival if confirmed in later-stage trials. The GMI analysis further supports the drug's potential to outperform existing therapies for individual patients.
TransCode Therapeutics is a clinical-stage company focused on immuno-oncology and RNA therapeutics for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets microRNA-10b, a well-documented biomarker of metastasis. The company is now evaluating dose-expansion strategies and plans to continue assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity. The latest updates on RNAZ are available in the company's newsroom at https://ibn.fm/RNAZ.
The announcement, disseminated via BioMedWire, highlights the role of specialized communications in bringing critical biotech developments to investors. BioMedWire is part of the Dynamic Brand Portfolio at IBN, which provides services such as InvestorWire for wire distribution, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and a suite of corporate communications solutions.
For investors and patients, the Phase 1a data represent a critical step forward in the development of a novel therapy for metastatic cancers, where treatment options are often limited and prognosis poor. If subsequent trials confirm these findings, TTX-MC138 could become a valuable addition to the oncology arsenal, addressing a significant unmet need. The absence of dose-limiting toxicities is particularly notable, as it may allow for combination therapies or extended treatment durations. As TransCode advances its clinical program, the medical community will watch closely for further evidence of efficacy and safety.
